Gertraud Hanft

Subclassification of α₁‐adrenoceptor recognition sites by urapidil derivatives and other selective antagonists

Gertraud Hanft · British Journal of Pharmacology · 1989 · 212 citations · Full text

Molecular Pharmacology, Adrenal Gland, Alpha 1A- +15

5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor

Gertraud Hanft, Christian Rugevics · European Journal of Pharmacology · 1988 · 211 citations

Molecular Pharmacology, Molecular Physiology, Sodium Homeostasis +6

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

Herbert Riechelmann, Alexander Sauter, Wolfram Golze et al. · Oral Oncology · 2008 · 195 citations

Medicine, Immunology, Pathology +8

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève et al. · European Journal of Cancer · 2010 · 109 citations

Oncology, Medicine, Pathology +9

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

Martin Sebastian, Martin Reck, Cornelius F. Waller et al. · Journal of Thoracic Oncology · 2010 · 109 citations · Full text

Bi 2536, Novel Plk-1 Inhibitor, Medicine +6